BsAbs
Why Bispecific Antibody Architecture Is a CMC Decision
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-01Jun 2, 2026
ADC Platform
From mAbs to ADCs: Rethinking the Platform Manufacturing Model
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-11May 11, 2026
Oral mAbs
Oral Delivery of Monoclonal Antibodies: The Pursuit Continues
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-04-26-PA-05Apr 7, 2026
Rebrand
Bio X Cell Unveils New Brand Identity, Reinforcing Global Leadership in Functional Antibody Solutions
Bio X Cell
PR-10-25-NI-12Oct 14, 2025
Collaboration
TegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for Cancer
Tegmine Therapeutics
PR-09-25-NI-05Sep 23, 2025
Charge Variants
Optimizing Charge and N-Glycan Profiles for CHO-Derived Fusion Proteins
Sojeong Lee, Ph.D.; Gyubeom Chin
Samsung Biologics
PAO-09-25-CL-03Sep 23, 2025
Antibody Research
Bio-Rad Extends Anti-Idiotypic Antibody and SpyCatcher Reagent Ranges for Bioanalysis and Antibody Drug Development Inbox
Bio Rad Laboratories, Inc.
PR-06-25-NI-05Jun 17, 2025
Nanobodies
Therapeutic Nanobodies and Intrabodies Rewriting the Rules of Target Engagement
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-25-NI-10May 27, 2025
Protein Design
Reprogramming the Rules: How AI Is Transforming De Novo Protein Design in Drug Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-25-NI-08Apr 15, 2025
Animal Testing
The End of an Era: What the FDA's Move Away from Animal Testing Means for Biopharma
Daniel Smith, Ph.D.
Nice Consulting
PAO-04-25-NI-06Apr 14, 2025
Small Biotechs
Five Small Biotechs to Watch: March 2025
David Alvaro, Ph.D.
Pharma's Almanac
PAO-02-25-NI-06Feb 28, 2025
Antibody
Timberlyne Therapeutics Secures $180M Series A to Advance CM313, a Promising Anti-CD38 Antibody for High-Need Diseases.
Timberlyne Therapeutics
PR-01-25-NI-07Jan 10, 2025
Agreement
Mediar Therapeutics and Lilly Sign Global Licensing Agreement to Advance WISP1 Antibody to Treat Idiopathic Pulmonary Fibrosis
Mediar Therapeutics
PR-01-25-NI-06Jan 10, 2025
Antibody
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
Spyre Therapeutics, Inc.
PR-12-24-NI-125Dec 3, 2024
Financing
EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics
EQT
PR-11-24-NI-116Nov 20, 2024
ADC
Chime Biologics and Waterstone Jointly Develop and Manufacture Antibody-Drug Conjugate (ADC)
Chime Biologics
PR-10-24-NI-91Nov 12, 2024
Announcement
Celebrating More than a Decade of Excellence at the World ADC Awards – Winners Announcement
World ADC
PR-10-24-NI-77Nov 8, 2024
Antibodies
Reshaping the Approach to Therapeutic Development with i-Bodies
AdAlta
PAO-10-24-RTM-12Nov 6, 2024
Appointment
Bio X Cell Announces Board of Director Appointments
Bio X Cell
PR-10-24-NI-45Oct 17, 2024
Bioassays
Developing a Toolbox of Functional Bioassays for Optimizing ADCC
Anke Hartung, Ph.D.,
Tanvex CDMO
PAO-09-24-CL-09Sep 30, 2024